Boditech Med, Selected for Two Dengue Diagnostic Products in WHO ERPD Review

[Financial News] Boditech Med announced on the 27th that its two dengue diagnostic products were finally selected in the World Health Organization (WHO)'s 'Expert Review Panel for Diagnostics (ERPD)' review. Recently, WHO announced a list of medicines and diagnostic devices related to Neglected Tropical Diseases (NTD), targeted for tropical disease eradication, and Boditech Med's products passed the ERPD review and were finally selected.
The selected products are the antigen diagnostic kit ‘ichroma Dengue NS1 Ag’ and the antibody diagnostic kit ‘ichroma Dengue IgG/IgM’. These are field diagnostic products based on Fluorescent Immunoassay (FIA) technology.
Both products meet the quality and performance standards set by WHO and provide diagnostic services that can effectively determine primary and secondary infections by conducting antigen and antibody tests concurrently.
This selection is one of WHO's emergency response measures to address the dengue fever, which is spreading worldwide. WHO operates the ERPD to quickly utilize suitable dengue diagnostic products in global healthcare settings.
ERPD is a system where independent experts evaluate in vitro diagnostic products with excellent performance that have not received WHO's Prequalification (PQ). It serves as an important criterion for the purchasing decisions of international organizations and governments.
In this evaluation, only seven products were selected worldwide, and Boditech Med's product was the only one listed among the fluorescent immunoassay methods. This recommendation is valid for one year and will be actively used for international procurement in response to infectious diseases.
According to WHO, the official number of dengue fever infections in 2024 exceeded 14 million, more than doubling from the previous year. Particularly, Brazil and other Latin American regions account for over 70% of total infections, highlighting the importance of early diagnosis and rapid response.
Choi Eui-Yeol, CEO of Boditech Med, said, “Passing this ERPD review is a result of our advanced technology and product reliability being internationally verified,” adding, “As the only product applying the fluorescent immunoassay method, we will continue to provide high-quality diagnostic solutions and play a leading role in global infectious disease management.”

vrdw88@fnnews.com Kang Jung-mo Reporter